AIM ImmunoTech Inc.

AIM ImmunoTech Inc. has released a new investor presentation, "The Ampligen Opportunity," detailing the potential of its drug Ampligen (rintatolimod) to enhance emerging RAS-targeted therapies for pancreatic cancer, specifically in combination with Revolution Medicines' daraxonrasib. The presentation outlines the scientific rationale, previously reported clinical observations, and upcoming milestones for the Phase 2 DURIPANC program, with topline results expected in Q1 2027 and further analyses in Q3 2027. The company believes Ampligen's immune-stimulating properties could complement daraxonrasib's targeted inhibition to potentially prolong clinical benefit.

AIM ImmunoTech announced its CEO, Thomas K. Equels, published an article in "Breaking Defense" advocating for proactive evaluation of broad-spectrum antiviral countermeasures. The article highlights the company's investigational drug, Ampligen (rintatolimod), and its potential as a prophylactic or early-onset antiviral against Ebola and its variants, citing preclinical research. Equels emphasizes integrating biodefense into military force protection planning, urging evaluation of promising countermeasures before new viral threats emerge.

AIM ImmunoTech Inc. announced that its CEO, Thomas K. Equels, published an article on Breaking Defense titled "Biodefense is force protection: Ready today, prepared for tomorrow." The article discusses the importance of military force readiness and highlights the potential of the Company's drug, Ampligen (rintatolimod), as a broad-spectrum early-onset and/or prophylactic antiviral therapeutic. It specifically addresses Ampligen's potential for Ebola virus disease and COVID-19, citing preclinical data and advocating for proactive evaluation of such countermeasures.

AIM ImmunoTech Inc. reported its financial results for the second quarter ended June 30, 2026, alongside significant operational advancements for its lead product, Ampligen. The company completed patient enrollment and Ampligen dosing in its Phase 2 DURIPANC study for metastatic pancreatic cancer and is preparing for a planned Phase 3 trial, with key data anticipated in Q1 and Q3 2027. Financially, AIM ImmunoTech reported a net loss of $3.8 million, or $0.43 per share, but strengthened its cash position to $9.9 million and regained compliance with NYSE American listing standards.

AIM ImmunoTech Inc. reported financial results for the second quarter ended June 30, 2026, alongside a significant business update. The company announced the completion of patient enrollment and Ampligen dosing in its Phase 2 DURIPANC study for metastatic pancreatic cancer, with key data anticipated in Q1 2027 and Q3 2027. For Q2 2026, AIM reported a net loss of $(3.8) million, or $(0.43) per share, but strengthened its balance sheet to $9.9 million in cash and regained full compliance with NYSE American listing standards. The company is also planning for a pivotal Phase 3 trial and exploring non-dilutive funding for Ebola initiatives.

AIM ImmunoTech reported a net loss of $3.79 million for the second quarter of 2026, an increase from $2.79 million in the prior year. Despite the increased loss, the company significantly improved its financial position, with cash and cash equivalents rising to $9.9 million and stockholders' equity turning positive to $7.74 million. The company also successfully regained compliance with NYSE American listing requirements. Operationally, progress continues on the DURIPANC Phase 2 clinical study for Ampligen in pancreatic cancer, with all subjects enrolled and detailed data anticipated later this year, alongside plans for a Phase 3 trial.

AIM ImmunoTech Inc. has mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026. This agreement allowed the company to sell common stock through an "at the market offering." The company will not incur any termination penalties as a result of this termination. From April 1, 2025, to July 31, 2026, AIM ImmunoTech sold 3,200,736 shares for approximately $2.8 million under this agreement.

AIM ImmunoTech Inc. announced the completion of dosing for the final subject in its Phase 2 DURIPANC clinical trial, evaluating Ampligen in combination with Imfinzi for metastatic pancreatic cancer, ahead of schedule. The company anticipates Primary Endpoint analysis to begin in December 2026 and topline results in Q1 2027. This follows encouraging exploratory observations from a Named Patient Program where Ampligen showed a median Overall Survival of 34.8 months in a specific patient subset, compared to 12.5 months for historical controls.

AIM ImmunoTech Inc. announced a Special Meeting of Stockholders to be held virtually on July 15, 2026. Shareholders will vote on several proposals, including a potential reverse stock split of up to 1-for-25, at the Board's discretion. Additionally, the company seeks approval for the issuance of common stock exceeding 19.99% of outstanding shares related to the exercise of Class H, I, and J warrants, and the conversion of two promissory notes, all for NYSE American compliance. The Board of Directors strongly recommends voting 'FOR' all proposals.

AIM ImmunoTech Inc. highlighted significant progress in its Ampligen pancreatic cancer development program, including the early completion of Phase 2 DURIPANC study enrollment and positive interim clinical updates. The company anticipates key milestones, with primary endpoint analysis expected in December 2026 and topline results in the first quarter of 2027. AIM believes these advancements position Ampligen for potential late-stage development and represent a critical value-inflection period for the company.